The reimbursement extension process for the multiple myeloma drug Kyprolis (carfilzomib, Amgen) has entered the final stage.

Its insurance drug price is being negotiated with the National Health Insurance Service. The discussion is likely for the use of Kyprolis in the Kyprolis+daratumumab+dexamethasone (DKd) regimen, which passed the Cancer Disease Review Committee (Cancer Quality Review) in April.

According to industry sources on the 14th, the NHIS started drug pricing negotiations with Amgen for the reimbursement expansion of Kyprolis 60mg this month.

The reimbursement standards for Kyprolis Inj was set in April as a ‘combination therapy used with daratumumab and dexa